194 related articles for article (PubMed ID: 28640362)
1. The impact of cancer drug wastage on economic evaluations.
Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
[TBL] [Abstract][Full Text] [Related]
2. Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review.
Lien K; Cheung MC; Chan KK
J Oncol Pract; 2016 Apr; 12(4):e369-79. PubMed ID: 26330534
[TBL] [Abstract][Full Text] [Related]
3. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
[TBL] [Abstract][Full Text] [Related]
4. The impact of pricing strategy on the costs of oral anti-cancer drugs.
Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
[TBL] [Abstract][Full Text] [Related]
5. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
6. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
7. Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies.
Leung CYW; Cheung MC; Charbonneau LF; Prica A; Ng P; Chan KKW
J Oncol Pract; 2017 Jul; 13(7):e646-e652. PubMed ID: 28605255
[TBL] [Abstract][Full Text] [Related]
8. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
[TBL] [Abstract][Full Text] [Related]
9. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
Parmar A; Jiao T; Saluja R; Chan KKW
Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
[TBL] [Abstract][Full Text] [Related]
10. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
11. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs.
Lam M; Olivier T; Haslam A; Tuia J; Prasad V
JAMA Oncol; 2023 Sep; 9(9):1238-1244. PubMed ID: 37471095
[TBL] [Abstract][Full Text] [Related]
12. A real-world analysis of cancer drug wastage due to oversized vials.
Liran O; Prus J; Gordon N; Almog V; Gruenewald T; Goldstein DA
J Am Pharm Assoc (2003); 2018; 58(6):643-646. PubMed ID: 30017368
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemotherapy drug wastage in a tertiary care hospital in India-A 3-month prospective and 1-year retrospective study.
Gopisankar MG; Wahlang J; Jagtap V; Sarkar C; Purnima Devi L; Harris C
Br J Clin Pharmacol; 2019 Oct; 85(10):2428-2435. PubMed ID: 31323137
[TBL] [Abstract][Full Text] [Related]
14. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
15. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
Skedgel C; Wranik D; Hu M
Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
[TBL] [Abstract][Full Text] [Related]
16. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
[TBL] [Abstract][Full Text] [Related]
17. Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center in India.
D'Souza VR; Palatty PL; George T; Adnan M; Rao S; Baliga MS
Indian J Cancer; 2019; 56(2):146-150. PubMed ID: 31062734
[TBL] [Abstract][Full Text] [Related]
18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
